Target intelligence / Profile preview

Bacterial DNA gyrase and topoisomerase IV (Bacillus anthracis) (DNA gyrase/Topo IV)

Target
DNA gyrase/Topo IV
Molecular classification
Enzyme, Type II topoisomerase, Isomerase
01

Overview

Bacterial DNA gyrase and topoisomerase IV are essential Type II topoisomerases in Bacillus anthracis that manage DNA topology during replication and transcription [4, 11]. DNA gyrase, a heterotetramer of GyrA and GyrB, introduces negative supercoils to relieve torsional stress ahead of the replication fork [4, 21]. Topoisomerase IV, composed of ParC (GrlA) and ParE (GrlB), is primarily responsible for decatenating daughter chromosomes to allow for proper segregation during cell division [1, 11]. These enzymes are the primary targets of fluoroquinolone antibiotics like ciprofloxacin, which is the standard treatment for anthrax [2, 8]. The drugs work by trapping the enzyme-DNA complex, creating a physical barrier that leads to permanent DNA strand breaks and rapid bacterial death [3, 13]. Resistance typically develops through specific mutations in the subunits' quinolone resistance-determining regions (QRDR), which impair drug binding [1, 4, 9].

Other names
Type II topoisomerasesGyrA/GyrBParC/ParEGrlA/GrlBDNA topoisomerase (ATP-hydrolyzing)
02

Mechanism of action

Inhibition of DNA synthesis and induction of cell death by stabilizing the covalent enzyme-DNA cleavage complex (interfacial inhibition), which prevents DNA religation and leads to lethal double-strand breaks [2, 3, 13].

03

Biological functions

DNA replicationDNA transcriptionDNA supercoilingChromosome segregationDNA decatenation
04

Disease associations

InfectionAnthrax
05

Safety considerations

Development of antibiotic resistanceTendonitis and tendon rupturePeripheral neuropathyCentral nervous system effectsQT interval prolongation
06

Interacting drugs

Ciprofloxacin

5 more in the full profile.

07

Biomarkers

Minimum inhibitory concentration (MIC)GyrA mutations (e.g., Ser85)ParC/GrlA mutations (e.g., Ser81)Bacterial load

Beyond the preview

Go deeper on Bacterial DNA gyrase and topoisomerase IV (Bacillus anthracis) (DNA gyrase/Topo IV).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacterial DNA gyrase and topoisomerase IV (Bacillus anthracis) (DNA gyrase/Topo IV).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call